Who will follow SK Bio with its homegrown COVID-19 vaccine?
By Kim, Jin-Gu | translator Alice Kang
22.04.27 06:00:48
가나다라
0
Important to secure comparator vaccines for clinical trials…global companies reluctant to cooperate
Eubiologics’ vaccine approved for Phase III trial in Africa… wasn’t able to secure comparator vaccines for trials in Korea
Cellid takes a two-track approach with basic vaccine·booster shot…GeneOne Life Science turns to booster shots
The marketing authorization for SK Bioscience’s homegrown COVID-19 vaccine 'GBP510' is nearing approval. If the drug is approved within the first half of the year as planned, GBP510 will become the first homegrown vaccine to be ever approved.
With the developer of the first vaccine set, who will be the No.2 and No.3 in line is gaining attention. Currently, Eubiologics, Cellid, and Geneone Life Science are speeding up trials for their COVID-19 vaccines.
The issue at hand is how the companies will secure a comparator vaccine for comparative trials. SK Bioscience had been able to quickly conduct a Phase III trial after securing the necessary comparator vaccines early on, other comp
Kim, Jin-Gu(kjg@dailypharm.com)
If you want to see the full article, please JOIN US (click)